Federal award (DEFINITIVE CONTRACT, fiscal year 2023)
Recipient: VENATORX PHARMACEUTICALS INC
Awarding agency: Department of Health and Human Services / Office of Assistant Secretary for Preparedness and Response
Funding agency: Department of Health and Human Services / Office of Assistant Secretary for Preparedness and Response
Period of performance: 2019-07-17 to 2025-09-30
Current total value of award: $125372213
Description: THE PURPOSE OF THIS MODIFICATION IS TO EXTEND THE PERIOD OF PERFORMANCE FOR CLIN0007 THROUGH SEPTEMBER 30, 2024, TO COMPLETE THE MANUFACTURE AND RELEASE OF THREE (3) VNRX-5133 DRUG SUBSTANCE PROCESS VALIDATION BATCHES, AT NO COST TO THE GOVERNMENT.